REVEALED: 7 - The Real Truth

1 Resilient Growth Stock to Buy Now and Hold Forever

Biopharmaceutical giant Gilead Sciences’ (GILD) shares have risen nearly 30% over the past year despite lingering macroeconomic challenges. Moreover, the company delivered solid growth last year and is expected to maintain its business momentum in 2023 and beyond, driven by its diversified medicines portfolio. Hence, investors could consider buying and…

StockNews.com · Mar 3, 2023

At buzzy health care business conference, investors fear the bubble will burst

JPMorgan's cheery confab returned to San Francisco, but the health care capitalists had economic anxiety, too.

WEKU · Jan 20, 2023

Health care investors convene in SF

Health care’s business class returned to San Francisco last week for JPMorgan’s annual health care confab

Salon · Jan 17, 2023

1 Stock to Buy This Week Following Its Recent Earnings Beat

Biopharmaceutical giant Gilead Sciences (GILD) reported better-than-expected third-quarter earnings and sales and raised its full-year guidance. Analysts see immense growth potential in the company’s HIV and oncology franchises, which should boost its performance in the upcoming quarters. Given its strong earnings, high profitability, discounted valuation, and attractive dividend, we think…

StockNews.com · Nov 7, 2022

It’s time for June Osborne to start winning in The Handmaid’s Tale

‘The Handmaid’s Tale’, returning to Channel 4 this weekend, has spent four seasons dragging June into the depths of hell. There’s nothing more to be learnt from her suffering, writes Amanda Whiting

The Independent UK · Oct 21, 2022

U.S. sends experimental antibody, antiviral drug to Uganda for Ebola outbreak

The United States sent Gilead Sciences' remdesivir and Mapp Biopharmaceutical Inc's experimental Ebola antibody drug MBP134 to Uganda last week to help safeguard healthcare workers responding to an outbreak that has infected 60 people and killed 44, U.S. government sources told Reuters.

Reuters · Oct 18, 2022

Vietnam Law May Impact Facebook, Twitter; Amazon Has A Sleep Tracker; India Lures Apple, Dell, HP: Top Financial Media Stories Thursday, Sept. 29

Reuters

Benzinga · Sep 29, 2022

It's Not Too Late for Investors to Start Buying GILD Stock

Biopharmaceutical giant Gilead Sciences (GILD) has delivered solid segmental sales growth in the last reported quarter. In addition, the company’s various research breakthroughs and drug approvals should further bolster its performance in the coming months. Given its robust profitability and discounted valuation, we think it could be wise to scoop…

StockNews.com · Sep 16, 2022

It’s time for June Osborne to start winning in The Handmaid’s Tale

‘The Handmaid’s Tale’ has spent four seasons dragging June into the depths of hell. There’s nothing more to be learnt from her suffering, writes Amanda Whiting

The Independent UK · Sep 14, 2022

Democratic candidate compares Florida to ‘Handmaid’s Tale’ in attack on DeSantis

1985 dystopian novel has become shorthand critique of many Republican policies

The Independent UK · Sep 11, 2022